Skip to main content

Viatris Inc EpiPen® Auto-Injectors revenue

  • VTRS · Nasdaq
  • Pharmaceuticals
  • S&P 500
$20.82+0.73%Close 13 Nov 2026

EpiPen® Auto-Injectors revenue at Viatris Inc came to $155.8M for the quarter to 30 Sep 2026, down 0.9% from a year earlier.

As Viatris Inc reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 5 Nov 2026.

By quarter

$87.0MDec 2023$80.2MMar 2024$115.5MJun 2024$123.2MSep 2024$73.1MDec 2024$96.7MMar 2025$136.8MJun 2025$157.2MSep 2025$79.0MDec 2025$101.1MMar 2026$129.2MJun 2026$155.8MSep 2026
Viatris Inc EpiPen® Auto-Injectors revenue, every reported period
Period endingEpiPen® Auto-Injectors revenueChange on a yearFiled
30 Sep 2026$155.8Mdown 0.9%5 Nov 2026
30 Jun 2026$129.2Mdown 5.6%6 Aug 2026
31 Mar 2026$101.1Mup 4.6%7 May 2026
31 Dec 2025$79.0Mup 8.1%26 Feb 2026
30 Sep 2025$157.2Mup 27.6%6 Nov 2025
30 Jun 2025$136.8Mup 18.4%7 Aug 2025
31 Mar 2025$96.7Mup 20.6%8 May 2025
31 Dec 2024$73.1Mdown 16.0%27 Feb 2025
30 Sep 2024$123.2Mdown 6.6%7 Nov 2024
30 Jun 2024$115.5Mdown 9.4%8 Aug 2024
31 Mar 2024$80.2Mdown 16.3%9 May 2024
31 Dec 2023$87.0Mup 27.4%28 Feb 2024
30 Sep 2023$131.9Mup 15.3%8 Nov 2023
30 Jun 2023$127.5Mup 19.7%7 Aug 2023
31 Mar 2023$95.8Mup 7.9%8 May 2023
31 Dec 2022$68.3Mup 25.6%27 Feb 2023
30 Sep 2022$114.4Mdown 11.7%7 Nov 2022
30 Jun 2022$106.5Mup 2.3%8 Aug 2022
31 Mar 2022$88.8Mdown 14.4%9 May 2022
31 Dec 2021$54.4M—28 Feb 2022
30 Sep 2021$129.5M—8 Nov 2021
30 Jun 2021$104.1M—9 Aug 2021
31 Mar 2021$103.7M—10 May 2021

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Viatris Inc: Brands revenue · Generics revenue · Lipitor revenue · Norvasc revenue · Lyrica ® revenue · Creon ® revenue · Viagra ® revenue · Influvac ® revenue · Zoloft ® revenue · Yupelri ® revenue · Celebrex ® revenue · Effexor ® revenue · Xalabrands revenue · Xanax ® revenue · Amitiza ® revenue · Dymista ® revenue · Developed Markets Segment revenue · Greater China revenue · Emerging Markets Segment revenue · Japan, Australia and New Zealand Segment revenue · financial statements

Every KPI and segment of VTRS, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.